Companies › CSPC Baike (Shandong) Biopharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Respiratory; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CM326 unclear - code-named drug | – | Phase 3 | Moderate to Severe Asthma | Dec 2028 |
| SYH9017 GLP-1 receptor agonist | – | Phase 1 | Overweight or Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06830343 | SYH9017 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Aug 2026 |
| NCT07372287 | CM326 | Phase 3 | Moderate to Severe Asthma | Respiratory | Dec 2028 |
No annotated target.
–
BrightGene Bio-Medical Technology Chiesi Farmaceutici JCR Pharmaceuticals Viking Therapeutics Aphaia Pharma US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.